Deepika Pakianathan - May 31, 2024 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
Director
Signature
/s/ Matthew T. Potter, Attorney-in-Fact for Deepika Pakianathan
Stock symbol
KPTI
Transactions as of
May 31, 2024
Transactions value $
-$880,693
Form type
4
Date filed
6/4/2024, 06:51 PM
Previous filing
May 30, 2024
Next filing
Jun 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$193K -202K -11.85% $0.95 1.51M May 31, 2024 See footnote F1, F4
transaction KPTI Common Stock Sale -$1.89K -1.98K -11.85% $0.95 14.7K May 31, 2024 See footnote F1, F5
transaction KPTI Common Stock Sale -$358K -357K -23.74% $1.00 1.15M Jun 3, 2024 See footnote F2, F4
transaction KPTI Common Stock Sale -$3.49K -3.49K -23.73% $1.00 11.2K Jun 3, 2024 See footnote F2, F5
transaction KPTI Common Stock Sale -$322K -338K -29.42% $0.95 810K Jun 4, 2024 See footnote F3, F4
transaction KPTI Common Stock Sale -$3.14K -3.3K -29.42% $0.95 7.91K Jun 4, 2024 See footnote F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9308 to $0.9996, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9643 to $1.06, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.93 to $0.9985, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.
F5 The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.